Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

18 trials with published results (41%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

4.5%

2 terminated out of 44 trials

Success Rate

93.1%

+6.6% vs benchmark

Late-Stage Pipeline

16%

7 trials in Phase 3/4

Results Transparency

67%

18 of 27 completed with results

Key Signals

18 with results93% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (3)
Early P 1 (1)
P 1 (15)
P 2 (13)
P 3 (7)

Trial Status

Completed27
Active Not Recruiting6
Recruiting5
Unknown3
Terminated2
Not Yet Recruiting1

Trial Success Rate

93.1%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT05910827Phase 1Recruiting

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT07217171Phase 1Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

NCT02466971Phase 3Active Not Recruiting

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

NCT07169734Phase 1RecruitingPrimary

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT06747585Phase 1Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT05827614Phase 1Active Not Recruiting

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT03983954Phase 1Active Not Recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NCT03738228Phase 1Completed

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT07147361Active Not Recruiting

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

NCT06543576Phase 1Recruiting

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

NCT06781073Phase 3CompletedPrimary

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

NCT02020707Phase 1Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02164461Phase 1Completed

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

NCT01649089Not ApplicableActive Not Recruiting

Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer

NCT05613283Active Not Recruiting

Primary Cervical Cancer Screening by Self-sampling HPV Test

NCT01693783Phase 2Completed

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

NCT05210348Unknown

Clinical Evaluation of Detection of High Risk HPV in Urine

NCT01759355Completed

Hybrid PET/MR in the Therapy of Cervical Cancer

NCT05013268Phase 1UnknownPrimary

Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma

NCT04976478Not Yet RecruitingPrimary

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Scroll to load more

Research Network

Activity Timeline